TONELLO, MARTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.399
AS - Asia 316
EU - Europa 248
OC - Oceania 1
Totale 2.964
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.392
CN - Cina 170
SG - Singapore 103
IT - Italia 67
FI - Finlandia 46
DE - Germania 33
SE - Svezia 28
FR - Francia 25
GB - Regno Unito 25
JP - Giappone 21
VN - Vietnam 16
UA - Ucraina 10
CZ - Repubblica Ceca 6
MX - Messico 5
BE - Belgio 4
IN - India 4
CA - Canada 2
HK - Hong Kong 2
IE - Irlanda 2
NL - Olanda 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
Totale 2.964
Salva come PNG Salva come JPEG
Città #
Fairfield 433
Chandler 277
Woodbridge 232
Ashburn 212
Houston 187
Ann Arbor 153
Seattle 133
Cambridge 129
Wilmington 115
Singapore 74
San Diego 49
Princeton 41
Des Moines 36
Medford 35
Beijing 33
Padova 33
Jacksonville 30
Roxbury 28
Helsinki 21
Nanjing 21
Dong Ket 16
Boardman 14
Mito 10
Nanchang 10
Santa Clara 10
New York 9
Tsukuba 9
Dearborn 8
Washington 8
Guangzhou 7
Brno 6
London 6
Hebei 5
Jinan 5
Milan 5
Allauch 4
Dallas 4
Hefei 4
Shenyang 4
Zhengzhou 4
Brussels 3
Frankfurt am Main 3
Kharkiv 3
Kilburn 3
Kunming 3
Los Angeles 3
Ningbo 3
Norwalk 3
Ogden 3
Rome 3
Auburn Hills 2
Bussero 2
Castelfranco Emilia 2
Changsha 2
Chongqing 2
Dongguan 2
Dublin 2
Florence 2
Hanover 2
Herndon 2
Hong Kong 2
Jiaxing 2
Nürnberg 2
Ponte di Piave 2
Prescot 2
Redwood City 2
Serrenti 2
Taiyuan 2
Acton 1
Arezzo 1
Arzignano 1
Auckland 1
Castello di Godego 1
Cerea 1
Changchun 1
Chiswick 1
Fuzhou 1
Haikou 1
Hangzhou 1
Harbin 1
Hounslow 1
Huzhou 1
Indiana 1
Lappeenranta 1
Leicester 1
Lisbon 1
Mandi 1
Montreal 1
Nanning 1
Orange 1
Pune 1
Quzhou 1
Taizhou 1
Toronto 1
Wandsworth 1
Xian 1
Totale 2.514
Salva come PNG Salva come JPEG
Nome #
Plasma exchange effectively removes 52- and 60-kDa anti-Ro/SSA and anti-La/SSB antibodies in pregnant women with congenital heart block. 139
Increased apoptosis in circulating lymphocyte cultures of anti-RNA polymerase III positive patients with systemic sclerosis. 111
Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report 111
Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review 107
Hypertension negatively affects the pregnancy outcome in patients with antiphospholipid syndrome. 103
Clinical and laboratory characteristics of isolated lupus anticoagulants 103
Prognosis of scleroderma renal crisis: a long-term observational study. 102
Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles 101
The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein i antibodies. A comparison with a homemade ELISA method 100
Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. 97
The clinical relevance of the IgM isotype of antiphospholipid antibodies in the vascular antiphospholipid syndrome 93
Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk 88
Confirmation of the initial antiphospholipid antibody positivity depends on antiphospholipid antibody profile 87
Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study. 86
Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study 85
Low titer, isolated anti Ro/SSA 60 kd antibodies is correlated with positive pregnancy outcomes in women at risk of congenital heart block 85
Short and long-term outcomes of children with autoimmune congenital heart block treated with a combined maternal-neonatal therapy. A comparison study 79
Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome 78
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. 78
Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. 76
Maternal autoantibody profiles at risk for autoimmune congenital heart block: a prospective study in high-risk patients 72
Risk-based secondary prevention of obstetric antiphospholipid syndrome. 70
Clinical value of anti-domain I-β2Glycoprotein 1 antibodies in antiphospholipid antibody carriers. A single centre, prospective observational follow-up study 69
Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome 67
Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. 67
[Clinical significance of fluoroscopic patterns specific for the mitotic spindle in patients with rheumatic diseases]. 65
Unstabilized DNA breaks in lymphocytes of patients with different subsets of systemic sclerosis 63
Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study 61
Detection of autoantibodies to the p200-epitope of SSA/Ro52 antigen. A comparison of two laboratory assays 60
Antiphosphatidylserine/prothrombin antibodies in antiphospholipid syndrome with intrauterine growth restriction and preeclampsia 60
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry) 59
IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers. 54
Longterm outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study 54
The efficacy and safety of second-line treatments of refractory and/or high risk pregnant antiphospholipid syndrome patients. A systematic literature review analyzing 313 pregnancies. 47
Unstabilized DNA breaks in lymphocytes of patients with systemic sclerosis. 42
IgG anti-Pentraxin 3 antibodies are a novel biomarker of ANCA-associated vasculitis and better identify patients with eosinophilic granulomatosis with polyangiitis 42
Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases 40
Impact of COVID-19 and COVID-19 vaccination on high-risk patients with Antiphospholipid Syndrome: a nationwide survey 29
High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets 17
High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets 16
CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies 14
Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome 12
Prevalence and adverse consequences of delayed diagnosis and misdiagnosis in thrombotic antiphospholipid syndrome. An observational cohort study and a review of the literature 9
Anti-phosphatidyl-serine/prothrombin antibodies (aPS/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity? 9
Risk factors for damage accrual in primary antiphospholipid syndrome: A retrospective single-center cohort study 8
Prevalence and adverse consequences of delayed diagnosis and misdiagnosis in thrombotic antiphospholipid syndrome. An observational cohort study and a review of the literature 2
Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome 1
Totale 3.018
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.451
article - articoli 13.451
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.902
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020474 0 0 0 42 63 43 82 69 65 45 25 40
2020/2021368 18 62 6 34 7 21 12 43 51 22 60 32
2021/2022579 22 54 87 38 20 36 24 61 27 12 47 151
2022/2023462 103 72 4 63 63 57 7 35 33 5 18 2
2023/2024324 13 53 41 26 22 51 26 14 13 5 25 35
2024/2025163 4 62 52 45 0 0 0 0 0 0 0 0
Totale 3.018